a Avanos. initiated S&IP performance year. transformation investment five morning, program. completed the for the accelerate was sale, you Good everyone. with pleased I'm last achievement savings we priorities against and and growth XXXX thank Steve. to Thanks outlined And as interest year cost increased your our in of
close second on S&IP First our top-line commitment. build on momentum; divestiture deliver TSA and the our
finally, their execute and Third, strategically accomplishments And our XXXX. leaner, deployed strategic I cost through review to agile in Four, these begin more capital accelerate growth. structure business. investment right-size to our to support expansion will M&A.
in First, XXXX. our we sustained top-line momentum
diluted share the our million, And earned our expectations. of year, For we per outlook. slightly to by exceeding adjusted ahead of sales the of end $XXX grew X% high $X.XX revised earnings
the X%. digestive our strong see products respiratory for businesses grew We these health Combined, continue Coolief, health year. and to demand throughout
X% organic XXX constant and in in to X% markets XXXX international from Additionally, currency. increased in sales the
This number coupled during our around inventory IV continued infusion continued with disruption working distributors a impacted with industry-wide customers. our third quarter. our challenges acute accounts of overall to The of shortage to all pump XX% we increase two partner for in pose conference performance issues call, exclusive increase the regulatory as our consolidation the for initiatives discussed saw the the and of customers pain year. sales As quarter our drug in pre-filler Leiters the for billing
drug addition, to take to ropivacaine to we interrupted. market, several it for year for was supply In months the last work to supply based is chain return beginning expect supply our the experience when on and
million market procedures a effective see for potential acute than more We XX US significant of large continued growth applicable annually, for surgical treatment. sparing pain addressable surgeons to given and opioid for pain, a demand growing
were force market but is healing, not c-sections difference cue specialties a penetration us in only meaningful orthopedic such pain on for as well-trained focused Our and OB/GYN new by make hysterectomy. in and and patients' in on free lives areas opioid growth sales expanding enabling
Our divestiture deliver second priority TSA our was to S&IP commitment. and on complete
as are scheduled our to commitments. progressing be We pleased TSA with
digit investment Our and with growth goal sustainable, over drive the achieving near priority accelerate single growth long-term to of strategic high was third time. to our
Our three International. pain, areas. were investments and Interventional focused key R&D on
Let me highlight some example.
awareness advance nerve First ablation. our and for our therapy, and CPTX significant These raise effective treatment OA of Coolief, first selected US knee we pain, RF we XXXX in unique market. the television are FDA investments only Genicular for business, in launched our code made interventional patient investments cleared in pain. the direct fastest-growing To commercials of patient expected
awareness. sales generated a lift which excited markets increase a our growth XX% about the in results normal over significant those saw patient expectation. Also, are We we in
community, our bolster investment further position differentiate we in our payer to research. the increased in Additionally and bullied clinical
for published seven Coolief of company result, in health the to intend XXXX Coolief's unexpected pain. one show for just and our knee hyaluronic near market. of for to the steroids details the target study more studies to treatment grown new for We're acid Coolief when to future. use from benefit driven billion in study against The optimistic economic and benefits could knee key against have publications about this expect dollar a XXXX. results As enable in publish pain us the Three which
Members contemplates addition leadership my which opioid ON-Q end, indoor on personally of crisis opioid than we reimbursement as and To members improved rather Furthermore, built was for When to Congress procedures our have I team we've reimbursement Crisis of with on But the working relations a we medical raising a to team reimbursement reduced US. single strengthened our In removal Today, a combat the Response team lobby alternatives of Opioid met financial several year expanding business. our have awareness, in our opioids incentives for of of like primarily we're half Coolief. initiatives encouraged a and this Coolief. therapy. person. for the ON-Q by also of the coverage to strengthened started adoption have for and advocating in such the non-opioid sparing government help nine Act focused I ago, efforts. devices capabilities. prescribing We're
to continued we of innovative in devices. to capabilities to build strengthen commercialize a R&D robust Second, new our medical and investing products pipeline
pain. from treat excited of eight the strong make by In FDA challenge initiatives investment companies across progress breakthrough selected around We increased are and inpatient more continue technologies XXX be opioid is our starting were breakthrough submissions signs to showing its returns. our one than addition; for methods to trial in innovation first we post-surgical of to Our new
year just our priority. areas focus accelerate become win strategic industry Turning double-digit growth plan channels XXXX distribution to investment business XXXX. evaluating and out strategic are market. growth. to where in and selected and to partners. our device position us has XXXX laid increase our framework team growth another we channel geographies made includes around Transforming acquiring grower how determining his investment a on Arjun growth which cost structure Sarker prioritize build we can the leadership our each our International, talent, and and internationals this of leads expect for top future three and prioritizing by we Restructure was this scale, rate rationalize business. to Overall, These we
we've to mentioned conference this transformation. previous As taking phased we're a on approach calls,
the As right phase first with organization a sizing our reminder, was model. to growth align our
more our reduce we've new initiated speed deployment will XXXX, available Second restructuring structural the was management efficient information enhance late up When making. IT cost, system. to inventory where of implementation decision completed and and it ERP improve in is the our enable our
shareholder I'm call as increased slated drive months anticipate I this continuous cost our These than year procurement. $XX a XXXX help end deploying million with through post-operative Senior global access our faster to initially manufacturing my Combining Chain demonstrates Moreover, reducing President Strategically broadens improvement of the Vice Dave healing have appointed rate. experience ago meeting and Dave network structure, our XXXX. it To our process, to senior member and site. capital deployment. this pleased team. The organic excited has my Ball leadership am growth reinvested programs and strengthens savings of accelerate orthopedic third to growth begin three previous will and I product supply, approach our later and two management our market final it's which optimize In to expectations be and access with him, phases we the be to is and disciplined phase costs Supply priority. drive will capital value acquisition, optimize pain $XX distribution growth. Game its as drive points, Global to by Procurement. M&A to efficiencies to of million the ability demonstrated the he the our in expect Ready was we to to transformation cost by our
met. ensuring We and will criteria meet to committed acquisition executing are our that deals discipline, we our remain are criteria
deals pipeline that remains in evaluating size robust are and Our potential our business. complement we will ranging
to I our in Now four want highlight priorities XXXX.
momentum accelerating to our growth. priority First, remains top-line drive top
investment. increase will We
to Chronic positions. of continue in Accelerating Coolief, expanding investing it momentum placement the our market We're and international as foundation our provides multiple in XX accelerate standard team us on chronic direct goal enteric track, business new small core is our bedside sales of our our US our new nazy trials also already as build and our market. digit and also care growth as products clinical feeding to to expanded bore our for the behind a To we've by successful care tracking to new grower mid-single maintain care technology see share leading the investment for tube advertising tubes. for We large near to expect XX%. leading launch into establish patient term. to
currently XX studies clinical planned the total over next years. and have We in three seven underway
health well effective the ablation six-month expect we be year, this shows hyaluronic study economic of study nerve that as than standard from half first the to cost more published, acid the care. During results of the as current is
Turning regaining sales acute of half focusing gradually year. pain. to anticipate the will to drug We're our supply the performers second as we accelerate growth meaningfully the improves in on begin
as Second, investing we management this growth strengthening on roles. Similar the international regional level post XXXX, grower framework, appropriate accelerated sales and marketing but growth of curtail our expansion Again, our future margin, XXXX, facing once to level of support our business and impact customer significant a investments initiatives. temporarily to established including Also and front, and continue see we'll in an will lead XXXX. our time. expect over will double-digit capabilities growth investments these margin will our we've we investment after we hiring for
This that providing execute we current streamline and cost, third systems across plans processes. to platform to quarter. more We infrastructure with and takeout second for $XX network our our the These of in deploying Turning we will capital the rollout enhancing $XX projects. and to stage details million year, $XX And phase IT XXXX million phase sourcing to simplifying expect in product includes in about will and simplify productivity establishment standardize transformation. plan. finally, and M&A global of new our of next we anticipate IT the of optimize million begin expect XXXX. our our million distribution multiple our enhance program Overall, $X the the of during savings will cost additional savings transport
XXXX device company. We are well-positioned a to pure-play succeed in as medical
will talented turn accelerate and we infrastructure, key Steve. scalable market, focused our Our to strategic gives physicians leading me over growing diverse that large portfolio in our the our growth. product I'll initiatives With call confidence and team on
